Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors
Open Access
- 3 July 2023
- journal article
- research article
- Published by Springer Nature in Nature Immunology
- Vol. 24 (8) , 1345-1357
Abstract
CD4+T cells play key roles in a range of immune responses, either as direct effectors or through accessory cells, including CD8+T lymphocytes. In cancer, neoantigen (NeoAg)-specific CD8+T cells capable of direct tumor recognition have been extensively studied, whereas the role of NeoAg-specific CD4+T cells is less well understood. We have characterized the murine CD4+T cell response against a validated NeoAg (CLTCH129>Q) expressed by the MHC-II-deficient squamous cell carcinoma tumor model (SCC VII) at the level of single T cell receptor (TCR) clonotypes and in the setting of adoptive immunotherapy. We find that the natural CLTCH129>Q-specific repertoire is diverse and contains TCRs with distinct avidities as measured by tetramer-binding assays and CD4 dependence. Despite these differences, CD4+T cells expressing high or moderate avidity TCRs undergo comparable in vivo proliferation to cross-presented antigen from growing tumors and drive similar levels of therapeutic immunity that is dependent on CD8+T cells and CD40L signaling. Adoptive cellular therapy (ACT) with NeoAg-specific CD4+T cells is most effective when TCR-engineered cells are differentiated ex vivo with IL-7 and IL-15 rather than IL-2 and this was associated with both increased expansion as well as the acquisition and stable maintenance of a T stem cell memory (TSCM)-like phenotype in tumor-draining lymph nodes (tdLNs). ACT with TSCM-like CD4+T cells results in lower PD-1 expression by CD8+T cells in the tumor microenvironment and an increased frequency of PD-1+CD8+T cells in tdLNs. These findings illuminate the role of NeoAg-specific CD4+T cells in mediating antitumor immunity via providing help to CD8+T cells and highlight their therapeutic potential in ACT.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (U01 DE028227)
This publication has 65 references indexed in Scilit:
- Single Naive CD4+ T Cells from a Diverse Repertoire Produce Different Effector Cell Types during InfectionCell, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- IMGT, the International ImMunoGeneTics Information SystemCold Spring Harbor Protocols, 2011
- Quality control and preprocessing of metagenomic datasetsBioinformatics, 2011
- High prevalence of low affinity peptide–MHC II tetramer–negative effectors during polyclonal CD4+ T cell responsesJournal of Experimental Medicine, 2011
- CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T LymphocytesCancer Research, 2010
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsJournal of Experimental Medicine, 2010
- Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cellsNature Medicine, 2009
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signalingJournal of Clinical Investigation, 2007